Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Menicucci, Andrea R ^a   Sureshchandra, Suhas ^b   Marzi, Andrea ^c   Feldmann, Heinz ^c   Messaoudi, Ilhem ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; G PROTEIN, VESICULAR STOMATITIS VIRUS; MEMBRANE PROTEIN; TRANSCRIPTOME; VIRUS ENVELOPE PROTEIN;

ANIMAL; BLOOD; CD8+ T LYMPHOCYTE; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENETICS; IMMUNOLOGY; MACACA FASCICULARIS; METABOLISM;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MACACA FASCICULARIS; MEMBRANE GLYCOPROTEINS; TRANSCRIPTOME; VIRAL ENVELOPE PROTEINS;

EID: 85018188050     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01032-8     Document Type: Article

References (26)

1. Howley, P. M. & Knipe, D. M. Fields Virology. Sixth edn, (Lippincott Williams & Witkins, 2013).
2. Kuhn, J. H. et al. Virus nomenclature below the species level: A standardized nomenclature for filovirus strains and variants rescued from cDNA. Archives of virology 159, 1229-1237, doi:10.1007/s00705-013-1877-2 (2014).
3. Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849-862, doi:10.1016/S0140-6736(10)60667-8 (2011).
4. (WHO), W. H. O. Ebola Situation Report, 30 March 2016 (2015).
5. Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature medicine 20, 1126-1129, doi:10.1038/nm.3702 (2014).
6. De Santis, O. et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 16, 311-320, doi:10.1016/S1473-3099(15)00486-7 (2016).
7. Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature medicine 11, 786-790, doi:10.1038/nm1258 (2005).
8. Wong, G. et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 32, 5722-5729, doi:10.1016/j.vaccine.2014.08.028 (2014).
9. Marzi, A. et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349, 739-742, doi:10.1126/science.aab3920 (2015).
10. Feldmann, H. et al. Effective post-exposure treatment of Ebola infection. PLoS pathogens 3, e2, doi:10.1371/journal.ppat.0030002 (2007).
11. Marzi, A., Hanley, P. W., Haddock, E., Martellaro, C., Kobinger, G. & Feldmann, H. Efficacy of Vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus Makona. Journal of Infectious Diseases 214, S360-S366, doi:10.1093/infdis/jiw218 (2016).
12. Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866, doi:10.1016/S0140-6736(15)61117-5 (2015).
13. Agnandji, S. T. et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med 374, 1647-1660, doi:10.1056/ NEJMoa1502924 (2016).
14. Regules, J. A. et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine-Preliminary Report. N Engl J Med, doi: 10.1056/ NEJMoa1414216 (2015).
15. Huttner, A. et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised doubleblind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15, 1156-1166, doi:10.1016/S1473-3099(15)00154-1 (2015).
16. Marzi, A. et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America 110, 1893-1898, doi:10.1073/ pnas.1209591110 (2013).
17. Heng, T. S., Painter, M. W. & Immunological Genome Project, C. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 9, 1091-1094, doi:10.1038/ni1008-1091 (2008).
18. Sadler, A. J. & Williams, B. R. Interferon-inducible antiviral effectors. Nature reviews. Immunology 8, 559-568, doi:10.1038/nri2314 (2008).
19. Zhu, W. et al. Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circulation research 105, 1240-1247, doi:10.1161/CIRCRESAHA.109.208785 (2009).
20. Shu, Q., Lennemann, N. J., Sarkar, S. N., Sadovsky, Y. & Coyne, C. B. ADAP2 Is an Interferon Stimulated Gene That Restricts RNA Virus Entry. PLoS pathogens 11, e1005150, doi:10.1371/journal.ppat.1005150 (2015).
21. Deenick, E. K., Ma, C. S., Brink, R. & Tangye, S. G. Regulation of T follicular helper cell formation and function by antigen presenting cells. Current opinion in immunology 23, 111-118, doi:10.1016/j.coi.2010.10.007 (2011).
22. Le Bon, A. et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470, doi:10.1016/S1074-7613(01)00126-1 (2001).
23. Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nature medicine 17, 1128-1131, doi:10.1038/nm.2447 (2011).
24. TW, H. B. & Girke, T. systemPipeR: NGS workflow and report generation environment. BMC Bioinformatics 17, 388, doi:10.1186/ s12859-016-1241-0 (2016).
25. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408, doi:10.1006/meth.2001.1262 (2001).
26. Ahn, K. et al. Selection of internal reference genes for SYBR green qRT-PCR studies of rhesus monkey (Macaca mulatta) tissues. BMC molecular biology 9, 78, doi:10.1186/1471-2199-9-78 (2008).